SeaSpine — Merger or Acquisition (October 2022)
17 slides from SeaSpine's merger presentation, Oct 11, 2022
Slide 1: Stronger Together: Building a Leading Global Spine & Orthopedics Company
Stronger Together: Building a Leading Global Spine & Orthopedics Company October 11, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication contains statements which, to the extent they are not statements of historical or present fact, constitute “forward-looking statements” under the securities laws. From time to time, oral or written forward-looking statements may also be included in other
Slide 3: Additional Information & Where to Find It
Additional Information & Where to Find It In connection with the proposed transaction, Orthofix intends to file with the SEC a registration statement on Form S-4, which will include a document that serves as a prospectus of Orthofix and a joint proxy statement of Orthofix and SeaSpine (the “joint pr
Slide 4: Complementary & Compelling Strengths
Complementary & Compelling Strengths #1 prescribed bone growth stimulator(1) portfolio in the U.S. Market leading cellular allograft(2) and only Lyograft tissue form Next generation differentiated artificial cervical disc Strong limb reconstruction & deformity correction portfolio Historically stron
Slide 5: Transformational Merger with Significant Strategic & Financial Benefits
Transformational Merger with Significant Strategic & Financial Benefits Driving Sustainable Growth & Value Creation Strengthened U.S. & international commercial reach Highly complementary spine & orthopedics portfolios One of the industry’s broadest biologics & regenerative technology offerings Mean
Slide 6: Transaction Summary
Transaction Summary Transaction Structure All-stock merger of equals: SeaSpine shareholders receive 0.4163 shares of Orthofix common stock per share of SeaSpine common stock Pro forma ownership: Approximately 56.5% Orthofix / Approximately 43.5% SeaSpine Leadership 9-member board of directors 5 desi
Slide 7: Expected Significant Growth & Value Creation
Expected Significant Growth & Value Creation Excludes net revenue synergies Estimated compound annual revenue growth rate from 2022 to 2025 Excludes stock-based compensation savings Cash + immediate availability under credit facility $ millions Year 3 Revenue (1) ~$1,000 Revenue Growth CAGR (2) Doub
Slide 8: $20B Total Addressable Market
$20B Total Addressable Market | 4.2% CAGR $7B of Focused Growth Segments* | 6.1% CAGR Complementary Portfolios Bridging Across Growing Markets SmartTRAK® 2022 – 2026 U.S. Estimates *Focused growth segments include Enabling Technologies, Motion Preservation, Interbody, DBM, LLIF/OLIF, MIS and Long Bo
Slide 9: Differentiated & Synergistic Enabling Technologies
Enabling technologies that service the full continuum of surgical care — from preoperative planning through surgical navigation Differentiated & Synergistic Enabling Technologies 7D FLASH™ Navigation System OrthoNext™ Preoperative Planning System
Slide 10: Leading Spine Portfolio
Cervical Thoracolumbar Fixation Interbodies Complementary, innovative suite of offerings that comprehensively address high-growth spine market segments Leading Spine Portfolio M6-C™ Artificial Cervical Disc WaveForm™ 3D Interbody Explorer® TO Expandable Interbody Forza™ TI Ti Spacer System with Nano
Slide 11: Leading Orthopedic Limb Reconstruction & Deformity Correction Portfolio
Complementary, innovative suite of offerings that comprehensively address high-growth orthopedic market segments with a leading pediatrics portfolio Leading Orthopedic Limb Reconstruction & Deformity Correction Portfolio Fitbone™ Intramedullary Nail System TrueLok™ EVO Ring Fixation System GBeam™ Fu
Slide 12: One of the Broadest Biologics & Regenerative Technology Offerings
CBM / Lyograft DBM Synthetics Growth factors Stimulation Full spectrum of biologics & regenerative technologies to meet procedural needs One of the Broadest Biologics & Regenerative Technology Offerings in the Industry Virtuos™ Lyograft Trinity Elite™ Allograft with Viable Cells OsteoTorrent™ Demine
Slide 13: Diversified & Strategic Business Mix in Growing Markets
Diversified & Strategic Business Mix in Growing Markets *LTM revenue as of September 30, 2022 Orthofix SeaSpine Combined Company * * $693M*
Slide 14: Combined Company Global Commercial Reach
Combined Company Global Commercial Reach Primary company offices Products Distributed in 68 countries Global manufacturing & R&D footprint ~1,600 employees 6 continents $557M* US $136M* International Countries of distribution *LTM revenue as of September 30, 2022
Slide 15: Foundation to Invest In, Strengthen & Attract Top Commercial Channel Partners
Foundation to Invest In, Strengthen & Attract Top Commercial Channel Partners Resources Pipeline Portfolio
Slide 16: Meaningful Revenue & Cost Synergy Opportunities
Meaningful Revenue & Cost Synergy Opportunities Revenue Addresses key product gaps for both companies (Orthofix: surgical navigation platform; SeaSpine: motion preservation) International cross-selling: Orthofix Spine & Orthopedic established commercial channels + SeaSpine biologics & 7D Flash Navig
Slide 17: Transformational Merger with Significant Strategic & Financial Benefits
Strengthened U.S. & international commercial reach Highly complementary spine & orthopedics portfolios One of the industry’s broadest biologics & regenerative technology offerings Meaningful cross-selling revenue & cost synergies and economies of scale Accelerated adoption of innovative and differen
SeaSpine Holdings — Merger or Acquisition (October 2022) on 6ix